Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

被引：77
|
作者：
Stuver, Robert [1 ]
Shah, Gunjan L. [2 ]
Korde, Neha S. [3 ]
Roeker, Lindsey E. [4 ]
Mato, Anthony R. [4 ]
Batlevi, Connie L. [1 ]
Chung, David J. [2 ]
Doddi, Sital [5 ]
Falchi, Lorenzo [1 ]
Gyurkocza, Boglarka [2 ]
Hamilton, Audrey [1 ]
Lin, Ya-Hui [5 ]
Jakubowski, Ann A. [2 ]
Joffe, Erel [1 ]
Landau, Heather L. [2 ]
Lin, Richard J. [2 ]
Mailankody, Sham [3 ]
Palomba, M. Lia [1 ]
Park, Jae H. [4 ]
Perales, Miguel-Angel [2 ]
Ponce, Doris M. [2 ]
V. Ramanathan, Lakshmi [5 ]
Salles, Gilles A. [1 ]
Scordo, Michael [2 ]
Seo, Susan K. [6 ]
Shah, Urvi A. [3 ]
Stein, Eytan M. [4 ]
Straus, David [1 ]
Usmani, Saad Z. [3 ]
Young, James W. [2 ]
Zelenetz, Andrew D. [1 ]
Noy, Ariela [1 ]
Vardhana, Santosha A. [1 ,7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, Div Subspecialty Med, New York, NY 10021 USA
[7] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER CELL | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1016/j.ccell.2022.05.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：590 / 591
页数：2
相关论文
共 50 条
  • [21] Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination
    Callegari, Chiara
    Lazzarotto, Davide
    Soravia, Alessandra
    Mutti, Martina
    Lauzzana, Pietro
    Peghin, Maddalena
    Cordella, Stefano
    Fanin, Renato
    Candoni, Anna
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 668 - 670
  • [22] Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
    James Brett Case
    Samantha Mackin
    John M. Errico
    Zhenlu Chong
    Emily A. Madden
    Bradley Whitener
    Barbara Guarino
    Michael A. Schmid
    Kim Rosenthal
    Kuishu Ren
    Ha V. Dang
    Gyorgy Snell
    Ana Jung
    Lindsay Droit
    Scott A. Handley
    Peter J. Halfmann
    Yoshihiro Kawaoka
    James E. Crowe
    Daved H. Fremont
    Herbert W. Virgin
    Yueh-Ming Loo
    Mark T. Esser
    Lisa A. Purcell
    Davide Corti
    Michael S. Diamond
    Nature Communications, 13
  • [23] SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
    Pulvirenti, Federica
    Garzi, Giulia
    Milito, Cinzia
    Sculco, Eleonora
    Sciannamea, Maddalena
    Napoli, Anna
    Cinti, Lilia
    Roberto, Piergiorgio
    Punziano, Alessandra
    Carrabba, Maria
    Piano Mortari, Eva
    Carsetti, Rita
    Antonelli, Guido
    Quinti, Isabella
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
    Case, James Brett
    Mackin, Samantha
    Errico, John M.
    Chong, Zhenlu
    Madden, Emily A.
    Whitener, Bradley
    Guarino, Barbara
    Schmid, Michael A.
    Rosenthal, Kim
    Ren, Kuishu
    Dang, Ha, V
    Snell, Gyorgy
    Jung, Ana
    Droit, Lindsay
    Handley, Scott A.
    Halfmann, Peter J.
    Kawaoka, Yoshihiro
    Crowe, James E., Jr.
    Fremont, Daved H.
    Virgin, Herbert W.
    Loo, Yueh-Ming
    Esser, Mark T.
    Purcell, Lisa A.
    Corti, Davide
    Diamond, Michael S.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [25] Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions
    Duminuco, Andrea
    Nardo, Antonella
    Orofino, Alessandra
    Giunta, Giuliana
    Conticello, Concetta
    Del Fabro, Vittorio
    Chiarenza, Annalisa
    Parisi, Marina S.
    Figuera, Amalia
    Leotta, Salvatore
    Milone, Giuseppe
    Cupri, Alessandra
    Cambria, Daniela
    Di Raimondo, Francesco
    Romano, Alessandra
    Palumbo, Giuseppe A.
    CANCER, 2024, 130 (01) : 41 - 50
  • [26] Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis
    Ordaya, Eloy E.
    Vergidis, Paschalis
    Razonable, Raymund R.
    Yao, Joseph D.
    Beam, Elena
    JOURNAL OF CLINICAL VIROLOGY, 2023, 160
  • [27] Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
    Ludovic Jondreville
    Maud D’Aveni
    Hélène Labussière-Wallet
    Amandine Le Bourgeois
    Alban Villate
    Ana Berceanu
    Silvia-Maria Bezsera
    Anne Thiebaut
    Marion Boissard-Simonet
    Marlène Legrand
    Jérôme Cornillon
    Marie-Thérèse Rubio
    Patrice Chevallier
    Stéphanie Nguyen
    Journal of Hematology & Oncology, 15
  • [28] Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
    Jondreville, Ludovic
    D'Aveni, Maud
    Labussiere-Wallet, Helene
    Le Bourgeois, Amandine
    Villate, Alban
    Berceanu, Ana
    Bezsera, Silvia-Maria
    Thiebaut, Anne
    Boissard-Simonet, Marion
    Legrand, Marlene
    Cornillon, Jerome
    Rubio, Marie-Therese
    Chevallier, Patrice
    Nguyen, Stephanie
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [29] Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
    Hites, Maya
    Lapique, Eva Larranaga
    Massonnaud, Clement R.
    Belhadi, Drifa
    Jamard, Simon
    Goehringer, Francois
    Danion, Francois
    Reignier, Jean
    de Castro, Nathalie
    Garot, Denis
    Lacombe, Karine
    Tolsma, Violaine
    Faure, Emmanuel
    Malvy, Denis
    Staub, Therese
    Courjon, Johan
    Cazenave-Roblot, France
    Riise, Anne Ma Dyrhol
    Leturnier, Paul
    Martin-Blondel, Guillaume
    Roger, Claire
    Akinosoglou, Karolina
    Le Moing, Vincent
    Piroth, Lionel
    Sellier, Pierre
    Lescure, Xavier
    Troseid, Marius
    Clevenbergh, Philippe
    Dalgard, Olav
    Gallien, Sebastien
    Gousseff, Marie
    Loubet, Paul
    Vardon-Bounes, Fanny
    Visee, Clotilde
    Belkhir, Leila
    Botelho-Nevers, Elisabeth
    Cabie, Andre
    Kotanidou, Anastasia
    Lanternier, Fanny
    Rouveix-Nordon, Elisabeth
    Silva, Susana
    Thiery, Guillaume
    Poignard, Pascal
    Carcelain, Guislaine
    Diallo, Alpha
    Mercier, Noemie
    Terzic, Vida
    Bouscambert-Duchamp, Maude
    Gaymard, Alexandre
    Trabaud, Mary-Anne
    JOURNAL OF INFECTION, 2024, 88 (03)
  • [30] Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants
    Kamboj, Mini
    Laracy, Justin C.
    Usiak, Shauna
    Babady, N. Esther
    Yan, Judy
    Seo, Susan K.
    JOURNAL OF INFECTION, 2023, 87 (03) : 282 - 285
12345